Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QTRX 
Quanterix Corp (QTRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: QTRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.05% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 243.83M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4 | Beta 1.04 | 52 Weeks Range 4.05 - 13.01 | Updated Date 11/12/2025 |
52 Weeks Range 4.05 - 13.01 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.4648 | Actual -0.73 |
Profitability
Profit Margin -73.47% | Operating Margin (TTM) -74.94% |
Management Effectiveness
Return on Assets (TTM) -14.28% | Return on Equity (TTM) -29.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 139332092 | Price to Sales(TTM) 1.87 |
Enterprise Value 139332092 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 46710797 | Shares Floating 40034407 |
Shares Outstanding 46710797 | Shares Floating 40034407 | ||
Percent Insiders 6.49 | Percent Institutions 73.28 |
Upturn AI SWOT
Quanterix Corp
Company Overview
History and Background
Quanterix Corporation was founded in 2007, focusing on ultrasensitive biomarker detection for life science research. It has evolved into a company offering platforms for single molecule counting to accelerate drug development and diagnostics.
Core Business Areas
- Simoa Consumables: These are reagents and assay kits used with the Simoa platform for biomarker detection.
- Simoa Instruments: These are the instruments, such as the HD-X and SR-X, that perform the ultrasensitive biomarker analysis.
- Accelerator Laboratory Services: Provides biomarker testing services to pharmaceutical and academic researchers.
Leadership and Structure
Masoud Toloue is the CEO. The company has a typical corporate structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Simoa HD-X Analyzer: An ultrasensitive immunoassay platform. Competitors include traditional ELISA assays and mass spectrometry-based methods. Specific market share data is not publicly available, but it holds a significant share in the ultrasensitive biomarker detection market.
- Simoa SR-X Analyzer: A benchtop version of the HD-X for research use. Similar competitor landscape as HD-X, focused on lower throughput needs.
- Simoa Consumables: Assay kits and reagents required for running samples. Strong recurring revenue stream.
Market Dynamics
Industry Overview
The biomarker analysis market is growing, driven by personalized medicine and drug development. There is increasing demand for accurate and sensitive detection methods.
Positioning
Quanterix is positioned as a leader in ultrasensitive biomarker detection. Its competitive advantage is its Simoa technology, which offers significantly higher sensitivity than traditional methods.
Total Addressable Market (TAM)
The total addressable market is estimated in the billions of dollars, encompassing diagnostics, drug discovery, and research. Quanterix is positioned to capture a growing share of this market with its proprietary technology.
Upturn SWOT Analysis
Strengths
- Proprietary Simoa technology
- High sensitivity and accuracy
- Established customer base
- Strong brand reputation
Weaknesses
- High cost of instruments and consumables
- Limited adoption in some areas of research
- Competition from established players
- Reliance on single technology platform
Opportunities
- Expanding applications in diagnostics and drug development
- Increasing demand for personalized medicine
- Partnerships with pharmaceutical companies
- Development of new Simoa-based assays
Threats
- Competition from new technologies
- Regulatory hurdles
- Economic downturn
- Patent infringement
Competitors and Market Share
Key Competitors
- ILMN
- DHR
- PKI
Competitive Landscape
Quanterix has a competitive advantage in ultrasensitive biomarker detection, but faces competition from larger, more established companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historically, Quanterix has experienced growth in revenue driven by increasing adoption of its Simoa technology. Growth has been driven by Pharma and Research.
Future Projections: Analysts project continued revenue growth driven by expansion into new markets and applications.
Recent Initiatives: Recent initiatives include expanding its assay menu, partnerships with pharmaceutical companies, and strategic acquisitions.
Summary
Quanterix is a company focused on ultrasensitive biomarker detection and driven to support the needs of drug and research companies. They have a good niche but are small compared to their key competitors. Their technology is powerful but can be costly. Growth is expected to continue; however, they face increasing competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (e.g., 10-K, 10-Q), Analyst Reports, Press Releases, Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data and financial information are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quanterix Corp
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2017-12-07 | President, CEO & Director Dr. Masoud Toloue Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 471 | Website https://www.quanterix.com |
Full time employees 471 | Website https://www.quanterix.com | ||
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.